ASXC — Asensus Surgical Income Statement
0.000.00%
- $81.58m
- $89.11m
- $8.58m
Annual income statement for Asensus Surgical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 8.53 | 3.17 | 8.23 | 7.09 | 8.58 |
Cost of Revenue | |||||
Gross Profit | -12.2 | -1.99 | -2.86 | -3.79 | -4.58 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 163 | 63.6 | 70 | 82.8 | 88 |
Operating Profit | -155 | -60.4 | -61.8 | -75.7 | -79.5 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -157 | -60.8 | -62.2 | -75.2 | -78.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -154 | -59.3 | -62.5 | -75.6 | -78.4 |
Net Income Before Extraordinary Items | |||||
Net Income | -154 | -59.3 | -62.5 | -75.6 | -78.4 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -154 | -60 | -62.5 | -75.6 | -78.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -5.88 | -0.84 | -0.283 | -0.316 | -0.313 |